China Pharma Holdings Inc. has announced an unregistered sale of equity securities in connection with a technology transfer agreement. The company’s wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into an agreement to acquire the ownership of an invention patent for Topiroxostat Nanoemulsion and its preparation method. As part of the transaction, China Pharma Holdings will issue 12,600,000 restricted shares of common stock at $0.70 per share, representing a total value of $8.82 million. The shares will be issued to the patent transferor or their designated third party, with closing expected by February 20, 2026. The issuance relies on an exemption from registration under Regulation S, as the transaction was negotiated and consummated outside the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Pharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-014338), on February 10, 2026, and is solely responsible for the information contained therein.